NDIA, March 5, 2018 -- Contrast Induced Nephropathy
Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25%increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles, puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure.
Major Key Players:
Pharming Group NV
Contrast Induced Nephropathy Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively.
Contrast Induced Nephropathy pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Contrast Induced Nephropathy - Competitive Analysis
Key players are making innovative developments in Contrast Induced Nephropathy industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
profylactisch FDA goedkeuring,Q3 en patiënt vriendelijker toediening enz..overname...na belachelijke koersdoel van Kempen...waardoor ze heel veel aandeeltjes beneden de 1 euro hebben kunnen HAMSTEREN!
Ff wat terug gehaald.....daarom komt €1,75 dichterbij...TRUST en GEDULD